VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | KdD VS Kd in R/R myeloma: TTP, TTNT and PFS2 data

Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, discusses updated data from the CANDOR (NCT03158688) study and reports on time to next treatment (TTNT), time to progression (TTP), and time to second objective disease progression (PFS2) in relapsed/ refractory multiple myeloma (R/R) patients receiving either carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). At a median of 27 months of follow-up, the median progression free survival with KdD was 28.6 months, compared to 15.2 months in the Kd arm. Dr Usmani reports that treatment with KdD improved TTP, TTNT and PFS2 in comparison to Kd. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter